Drug Profile
Artemether sublingual - LondonPharma/Malaria Research Company
Alternative Names: Artemether sublingual spray; ArTiMist; ArTiMist 6; LON 002Latest Information Update: 20 Oct 2021
Price :
$50
*
At a glance
- Originator ProtoPharma
- Developer LondonPharma; Malaria Research Company; ProtoPharma
- Class Anthelmintics; Antifungals; Antimalarials; Antineoplastics; Antiprotozoals; Artemisinins; Fluorenes; Skin disorder therapies; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Immunomodulators; Mitochondrial protein inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Cancer; Falciparum malaria; Solid tumours
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Sublingual, Spray)
- 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours in Africa (Sublingual, Spray)
- 03 Apr 2017 Preregistration for Falciparum malaria (In children) in Australia (Sublingual) prior to April 2017